Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
Last trade$58.87
Day change-$0.25 (-0.42%)
Day range$57.85 – $59.31
Volume220,905
Market cap$1.71B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.71B
Price / earnings
17×
Price / book
2.07×
Price / sales
1.94×
EV / sales
1.73×
EV / EBITDA
44.19×
Profitability
Earnings per share
$3.48
Return on assets
10.57%
Return on equity
12.18%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.45×
Quick ratio
4.61×
Cash ratio
1.96×
Cash flow
Price / cash flow
12.69×
Price / free cash flow
17.49×
Free cash flow
$97.89M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for INSP, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$206.7M
$200.58M
$204.58M
$269.08M
$224.5M
$217.09M
$201.32M
$239.72M
Cost of revenue
$28.84M
$29.12M
$27.67M
$36.07M
$31.77M
$34.67M
$30.71M
$35.99M
Gross profit
$177.86M
$171.46M
$176.91M
$233.01M
$192.73M
$182.41M
$170.61M
$203.73M
Selling, general and administrative
$184.4M
$147.28M
$152.2M
$161.95M
$158.87M
$159.52M
$144.29M
$141.51M
Research and development
$22.18M
$24.7M
$25.83M
$24.94M
$24.21M
$26.21M
$27.8M
$30.34M
Total operating expenses
$206.57M
$171.97M
$178.03M
$186.9M
$183.08M
$185.73M
$172.09M
$171.85M
Operating income
-$28.72M
-$514K
-$1.12M
$46.11M
$9.64M
-$3.32M
-$1.49M
$31.88M
Interest expense
$0
$0
$0
-$122K
$0
$0
$0
-$22K
Income before taxes
-$25.01M
$3.12M
$2.4M
$50.32M
$13.55M
-$2.33M
$4.16M
$36.64M
Income taxes
-$616K
$2.8M
$13.69M
-$85.77M
$3.62M
$1.26M
$1.17M
$1.41M
Net income
-$24.39M
$314K
-$11.29M
$136.09M
$9.93M
-$3.59M
$2.99M
$35.22M
Net income attributable to common shareholders
-$24.39M
$314K
-$11.29M
$136.09M
$9.93M
-$3.59M
$2.99M
$35.22M
EBITDA
-$23.58M
$4.08M
$3.99M
$49.93M
$13.32M
$98K
$1.56M
$34.36M
Basic earnings per share
-$0.84
$0.01
-$0.39
$4.70
$0.34
-$0.12
$0.10
$1.18
Diluted earnings per share
-$0.84
$0.01
-$0.39
$4.60
$0.34
-$0.12
$0.10
$1.12
Recent news
Company coverage with links to the original publishers.
Inspire Medical Systems (INSP) is positioned for solid growth despite a 32.5% year-to-date stock decline. The company faces near-term headwinds from $120 million in annual coding and reimbursement disruptions, but benefits from strong Inspire V adoption, improved clinical evidence, and a new CPT code effective in 2028. Project Horizon initiatives are expected to support low-single-digit revenue growth in 2027, though GLP-1 adoption and international weakness remain concerns.
Inspire Medical Systems (INSP) shares gained 12.1% over three months despite a 7.9% revenue decline and 62.2% drop in adjusted Q3 EPS. Reimbursement issues cost the company $30M in Q3 revenues with a projected $120M full-year 2026 impact. The company targets low-single-digit revenue growth in 2027 through Project Horizon and battery replacement procedures, though reimbursement execution remains a key risk factor.
Inspire Medical Systems beat Q3 earnings expectations with $0.14 EPS versus consensus of $0.10, and revenues of $206.7M slightly above estimates. However, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends ahead of the earnings release. The stock has underperformed the S&P 500 by 37% year-to-date, and near-term underperformance is expected despite the positive earnings surprise.
Inspire Medical Systems (INSP) reported Q3 2026 revenue of $206.7 million, down 7.9% year-over-year, though it beat consensus estimates by 1.17%. EPS of $0.14 significantly exceeded expectations of $0.10 (+40%), but declined from $0.38 a year ago. U.S. revenue fell 7.9% to $197.49 million, while international revenue declined 8.9% to $9.21 million. The stock has been assigned a Zacks Rank #4 (Sell) rating.
Inspire Medical Systems (INSP) shares gained 47.8% over three months as reimbursement uncertainty eases following new CPT code approvals and better-than-expected Q2 results. The company reported $200.6M in revenues and 14 cents adjusted EPS, while Project Horizon aims to redirect $30M in annualized savings toward growth initiatives. However, near-term sales remain disrupted and full execution risks persist.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.